Formulation Development
Omega Therapeutics Announces Strategic Research Collaboration With Stanford University School of Medicine
Omega Therapeutics, Inc. recently announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic…
TFF Pharmaceuticals & Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody Neutralizes SARS-CoV-2 Infection & Reduces Viral Load
TFF Pharmaceuticals, Inc. and Augmenta Bioworks recently announced the publication of a research paper highlighting positive preclinical study results of AUG-3387, a monoclonal antibody (mAb)…
Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies
Progenity, Inc. recently announced the United States Patent and Trademark Office (USPTO) has issued four patents related to its ingestible technologies for delivery of therapeutics…
LEXEO Therapeutics & FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development & Manufacturing of Gene Therapies for Genetic Diseases
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies recently announced a strategic collaboration to support the development and manufacturing of LEXEO’s AAV-mediated gene therapies. FUJIFILM Diosynth Biotechnologies…
Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer
Veru Inc. recently announced it has enrolled the first patient in its Phase 3 ARTEST registration trial of enobosarm, an oral selective androgen receptor (AR)…
PCI Pharma Services Announces the Acquisition of LSNE to Add End-to-End Global Sterile Fill-Finish & Lyophilization Manufacturing Capabilities
PCI Pharma Services (PCI) recently announced it has signed a definitive agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization (CDMO)….
Pace Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services
Pace Analytical Life Sciences, LLC, a subsidiary of Pace Analytical Services, LLC, a full-service contract development and manufacturing organization (CDMO), recently announced that it has acquired Velesco….
Centogene & Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
Centogene N.V. and Twist Bioscience Corporation recently announced they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases…..
Acer Therapeutics & Relief Therapeutics Announce FDA Acceptance for Filing of NDA
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA recently announced the US FDA has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the….
Timber Pharmaceuticals Reports Positive Top-Line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate-to-Severe Congenital Ichthyosis
Timber Pharmaceuticals, Inc. recently announced positive top-line data from its Phase 2b CONTROL study evaluating TMB-001, an investigational topical isotretinoin formulated using Timber's patented IPEG…
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals, Strengthening its CNS Product Portfolio
Supernus Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc. recently announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share…
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Pacira BioSciences, Inc. and Flexion Therapeutics, Inc. recently announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash,…
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
Fortress Biotech, Inc. and a company it founded, Caelum Biosciences, Inc. recently announced the closing of AstraZeneca’s acquisition of Caelum, pursuant to the Development, Option…
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of Monoclonal Antibody
Acumen Pharmaceuticals, Inc. recently announced dosing of the first patient in INTERCEPT-AD, the Phase 1 placebo-controlled, single- and multiple-dose clinical trial of ACU193, a monoclonal…
Albireo Announces Exclusive Licensing Agreement With Jadeite Medicines
Albireo Pharma, Inc. recently entered into an exclusive licensing agreement with Jadeite Medicines, Inc. for the development and commercialization of Bylvay (odevixibat) in Japan for…
Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
Processa Pharmaceuticals, Inc. recently announced it has been cleared by the US FDA to proceed with a Phase 2a clinical trial of PCS12852 in patients…
Agenus to Receive $20-Million Milestone Payment From Bristol Myers Squibb With Dosing of First Patient
Agenus Inc. recently announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific….
Metrics Contract Services Enters Partnership to Develop Oncology Drug
Metrics Contract Services, the US-based contract pharmaceutical development and manufacturing division of Mayne Pharma, recently announced the signing of a development and manufacturing agreement with….
MilliporeSigma Launches Excipient Technology Platform for Viscosity Reduction of Protein-Based Therapeutics
MilliporeSigma has recently launched a new Viscosity Reduction Excipient Platform to reduce the viscosity and help overcome manufacturing and formulation challenges associated with….
MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population
MannKind Corporation recently announced the enrollment of the first pediatric patient in the INHALE-1 study. The multi-center study will evaluate the efficacy and safety of….